Actionable news
0
All posts from Actionable news
Actionable news in ICPT: Intercept Pharmaceuticals, Inc.,

Relypsa Inc (RLYP) and Intercept Pharmaceuticals Inc (ICPT) Attract Analysts In Light of Potential Acquisition and Favorable FDA’s Panel Outcome

SHARE ON:

Healthcare analysts weigh in on drug makers Relypsa Inc (NASDAQ:RLYP) and Intercept Pharmaceuticals Inc (NASDAQ:ICPT), as one explores potential sale and the other gets closer to FDA approval. Let’s take a closer look.

Relypsa Inc

Relypsa shares skyrocketed nearly 68% yesterday following a Reuters’ article which indicated that Relypsa has received multiple overtures from potential buyers and as a consequence is working with an investment bank to review offers.

Wedbush analyst Liana Moussatos was the first to comment: “We previously looked at the phosphate binder market and based on Symphony Health estimates for total prescriptions, we calculated Renagel and Renvaler (both have the sevelamer polymer as the active ingredient) together have over 80% of the total phosphate binder annual prescriptions and that Sanofi has been clearly successful in our view at counter detailing metal-based phosphate binders. Sanofi and Relypsa have a two year co-detailing contract for Veltassa and we believe Sanofi’s involvement – especially with their salespeople’s presumed long-term relationships with nephrologists who prescribe phosphate...


More